Regeneron received FDA approval for Otarmeni, the first gene therapy to restore normal hearing in children born with otoferlin deafness. The treatment targets a rare condition affecting 2-8% of congenital hearing loss cases. Unlike cochlear implants, the therapy provides natural hearing without robotic sound quality or battery limitations.

The company plans to provide the therapy free to qualifying children, a strategy that could build goodwill while potentially capturing market share. With an 80% success rate in clinical trials, the treatment offers significant clinical value. Industry analysts will watch how this pricing model affects Regeneron's financial performance.

Several companies, including Eli Lilly and international firms, are developing competing therapies for otoferlin deafness. The approval sets a precedent for genetic hearing treatments and may accelerate investment in the broader biotechnology space, particularly for rare conditions with limited patient populations but high unmet medical needs.